Daré Bioscience Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Die Gewinne von Daré Bioscience sind jährlich um durchschnittlich 22.3% gestiegen, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen um 9.1% gestiegen sind. Die Umsätze sind jährlich um rückläufig 11.3% gestiegen.
Wichtige Informationen
22.27%
Wachstumsrate der Gewinne
42.32%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 5.95% |
| Wachstumsrate der Einnahmen | -11.30% |
| Eigenkapitalrendite | -471.37% |
| Netto-Marge | -1,300.66% |
| Letzte Ertragsaktualisierung | 31 Dec 2025 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Women’s Health Pipeline Risks Will Persist Yet Long Term Potential Will Eventually Emerge
Catalysts About Daré Bioscience Daré Bioscience develops women’s health products across sexual health, contraception, menopause, vaginal health and infectious disease, with a focus on differentiated formulations built around known compounds. What are the underlying business or industry changes driving this perspective?
Women’s Health Pipeline And Dual 503B Pathway Will Transform Long Term Earnings Potential
Catalysts About Daré Bioscience Daré Bioscience focuses on developing and commercializing women’s health products across sexual health, contraception and menopause. What are the underlying business or industry changes driving this perspective?
Women’s Health Platform And 503B Launches Will Reshape Long-Term Outlook
Catalysts About Daré Bioscience Daré Bioscience is a women's health company focused on developing and commercializing clinically supported products across sexual health, contraception, menopause and vaginal health. What are the underlying business or industry changes driving this perspective?We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms
Daré Bioscience (NASDAQ:DARE) is trading 6.5% higher after the company announced positive data from its Phase 1/2 clinical trial of investigational intravaginal ring, DARE-HRT1, to treat the vasomotor symptoms and genitourinary syndrome associated with menopause. The drug is designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy regimen. The topline data from the study showed improvement in both vasomotor symptoms as well as vaginal symptoms of menopause. The primary objective or the main goal of the study was to demonstrate the safety, tolerability, and pharmacokinetics (PK) of two different dose combinations over 12 weeks of use. The company said the levels of estradiol released from both the lower and higher dose formulation of DARE-HRT1 evaluated in the study achieved statistically significant improvement. Menopausal symptoms, including hot flashes and night sweats, were reduced compared with baseline in both DARE-HRT1 dose groups. The topline PK data from the study will be available later in Q4.Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive
Daré Bioscience (NASDAQ:DARE) is trading 5.3% higher after the U.S. Food and Drug Administration approved its investigational device exemption (IDE) application to conduct an efficacy study of investigational hormone-free monthly intravaginal contraceptive, Ovaprene. The IDE approval will mean the FDA determined that the company provided sufficient data to support the initiation and conduct of the study. The submission included the results of the postcoital test clinical study of Ovaprene, in which the therapy prevented sperm from entering the cervical canal across all women and all cycles evaluated. The company is targeting mid-year 2023 to begin study recruitment.Dare Bioscience reports positive progress for cream for female sexual arousal disorder
Dare Bioscience (NASDAQ:DARE) said that based on an interim analysis of phase 2b data for its sildenafil cream for female sexual arousal disorder, enrollment in the study will complete in Q4. Total enrollment will be 150 women. The company anticipates a top-line data announcement in Q2 2023. Sildenafil is the active ingredient in Viagra, a pill approved for erectile dysfunction. Dare (DARE) noted that its sildenafil cream is designed to be applied to the vaginal tissue just prior to intercourse to increase blood flow directly to the tissue. Seeking Alpha Quant Rating views Dare (DARE) as a hold with high marks for growth and revisions.Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
Women health firm Daré Bioscience (NASDAQ:DARE) announced an exclusive license agreement with clinical-stage biopharma firm Organon (NYSE:OGN) to commercialize Xaciato, DARE's treatment of bacterial vaginosis in patients 12 years of age and older. Under the agreement, Daré will receive a $10M upfront payment from Organon and is eligible to receive potential milestone payments of up to $182.5M and tiered double-digit royalties based on net sales. Xaciato will be commercially available in the U.S. in Q4, DARE said. The companies entered into the agreement on March 31.Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Diving Back Into Daré Bioscience Again
Today, we revisit women's health concern Daré Bioscience for the first time in nearly a year. This small cap concern just received its first FDA approval and is advancing other candidates in its pipeline. A full investment analysis follows in the paragraphs below.We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching
While Daré Bioscience, Inc. ( NASDAQ:DARE ) might not be the most widely known stock at the moment, it led the NASDAQCM...Aufschlüsselung der Einnahmen und Ausgaben
Wie Daré Bioscience Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Dec 25 | 1 | -13 | 9 | 6 |
| 30 Sep 25 | 0 | -17 | 9 | -6 |
| 30 Jun 25 | 0 | -19 | 9 | -5 |
| 31 Mar 25 | 0 | -2 | 9 | 0 |
| 31 Dec 24 | 0 | -4 | 9 | 14 |
| 30 Sep 24 | 2 | -4 | 10 | -7 |
| 30 Jun 24 | 3 | -7 | 11 | -3 |
| 31 Mar 24 | 3 | -29 | 11 | -5 |
| 31 Dec 23 | 3 | -30 | 12 | 0 |
| 30 Sep 23 | 1 | -41 | 12 | 1 |
| 30 Jun 23 | 0 | -40 | 12 | -2 |
| 31 Mar 23 | 10 | -31 | 12 | -1 |
| 31 Dec 22 | 10 | -31 | 11 | 0 |
| 30 Sep 22 | 10 | -25 | 10 | 24 |
| 30 Jun 22 | 10 | -30 | 10 | 30 |
| 31 Mar 22 | 0 | -40 | 9 | 31 |
| 31 Dec 21 | 0 | -39 | 8 | 31 |
| 30 Sep 21 | 0 | -38 | 8 | 30 |
| 30 Jun 21 | 0 | -33 | 7 | 26 |
| 31 Mar 21 | 0 | -30 | 7 | 24 |
| 31 Dec 20 | 0 | -27 | 7 | 21 |
| 30 Sep 20 | 0 | -23 | 6 | 17 |
| 30 Jun 20 | 0 | -19 | 6 | 12 |
| 31 Mar 20 | 0 | -16 | 6 | 9 |
| 31 Dec 19 | 0 | -15 | 5 | 9 |
| 30 Sep 19 | 0 | -14 | 5 | 8 |
| 30 Jun 19 | 0 | -13 | 5 | 8 |
| 31 Mar 19 | 0 | -12 | 5 | 7 |
| 31 Dec 18 | 0 | -17 | 5 | 6 |
| 30 Sep 18 | 0 | -23 | 4 | 5 |
| 30 Jun 18 | 0 | -22 | 4 | 4 |
| 31 Mar 18 | 0 | -19 | 3 | 2 |
| 31 Dec 17 | 0 | -12 | 2 | 1 |
| 30 Sep 17 | 0 | -3 | 2 | 0 |
| 30 Jun 17 | 0 | -1 | 1 | 0 |
| 31 Mar 17 | 0 | -1 | 0 | 0 |
| 31 Dec 16 | 0 | -1 | 0 | 0 |
Qualität der Erträge: DARE ist derzeit unrentabel.
Wachsende Gewinnspanne: DARE ist derzeit unrentabel.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: DARE ist unrentabel, hat aber in den letzten 5 Jahren die Verluste mit einer Rate von 22.3% pro Jahr reduziert.
Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von DARE verglichen werden, da das Unternehmen derzeit nicht profitabel ist.
Erträge im Vergleich zur Industrie: DARE ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Pharmaceuticals (-5%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: DARE hat eine negative Eigenkapitalrendite (-471.37%), da es derzeit unrentabel ist.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/14 06:39 |
| Aktienkurs zum Tagesende | 2026/05/14 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Daré Bioscience, Inc. wird von 5 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Douglas Tsao | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |